Preliminary research has revealed that some excipients used in common medications may interact with important human enzymes and receptors.
List view / Grid view
Novartis Institutes for BioMedical Research (NIBR)
Filter the results
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer...